SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Acceleron Pharma Inc. (XLRN) .
Criteria proven by this page:
- VALUE (20/100, Fail) — analyst consensus target implies downside from the current price ($150.00, 16.1%).
- Analyst consensus target $150.00 (-16.1% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 39/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
20/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — XLRN
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio109.73
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-2.92
Book Value / Share$0.00
Revenue / Share$1.63
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$150.00 (-16.1%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2011 |
$1.58 |
$80.91M |
$36.27M |
44.8% |
| 2012 |
$-1.55 |
$15.25M |
$-32.58M |
-213.6% |
| 2013 |
$-1.04 |
$57.23M |
$-21.9M |
-38.3% |
| 2014 |
$-1.63 |
$14.63M |
$-51.26M |
-350.3% |
| 2015 |
$-1.92 |
$18.1M |
$-63.89M |
-353.1% |
| 2016 |
$-1.52 |
$27.77M |
$-57.01M |
-205.3% |
| 2017 |
$-2.68 |
$13.48M |
$-108.45M |
-804.5% |
| 2018 |
$-2.59 |
$13.99M |
$-118.87M |
-849.6% |
| 2019 |
$-2.38 |
$73.99M |
$-124.86M |
-168.7% |
| 2020 |
$-2.92 |
$92.52M |
$-166.03M |
-179.4% |
